MEDOSOME BIOTEC LLC
- BLOOMINGTON, IN 47401
- mdbiotec.com (company website, opens in a new tab)
- Partnership or Limited Liability Partnership
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
MEDOSOME BIOTEC LLC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About MEDOSOME BIOTEC LLC
- Headquarters
- BLOOMINGTON, IN 47401
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIMJJJFTJE1SB5
- CAGE75Z81
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 18 awards
- Total awarded
- $12,914,262
- By phase
- STTR Phase I: 9
- SBIR Phase I: 4
- STTR Phase II: 4
- SBIR Phase II: 1
- By agency
- Department of Health and Human Services: 18
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2024: 1
- 2023: 1
- 2022: 1
- 2021: 1
- 2020: 2
- 2019: 3
- 2017: 3
- 2016: 4
- 2015: 2
Awards (most recent first)
Metabolism and Mitochondrial Energetics Therapy for Septic Shock
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $350,000
Sep 12, 2024 – Sep 11, 2025
Solicitation PA23-232 (2023) · Topic 300 · Research partner: NORTHWESTERN UNIVERSITY
Engineering next generation probiotics for delivery of therapeutics
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $325,000
Aug 1, 2023 – Jul 31, 2024
Solicitation PA22-176 (2022) · Topic NCATS
A method for accurate and sensitive detection of HIV drug-resistant minority variants
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $1,999,999
Jul 20, 2022 – Jun 30, 2024
Solicitation PA20-265 (2020) · Topic NIAID · Research partner: UNIVERSITY OF FLORIDA
Next generation quantitative HCV drug resistance assay
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $1,611,097
Jul 20, 2021 – Jun 30, 2023
Solicitation PA20-260 (2020) · Topic 300
Personalized dosing of dichloroacetate for the treatment of rare and common diseases
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $2,978,087
Jul 14, 2020 – Jun 30, 2023
Solicitation PA19-271 (2019) · Topic NICHD · Research partner: UNIVERSITY OF FLORIDA
Prevention of White Matter Injury in Premature Infants
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $1,693,867
Jun 1, 2020 – May 31, 2022
Solicitation PA18-575 (2018) · Topic NICHD · Research partner: UNIVERSITY OF FLORIDA
Optimization of recombinant probiotics for oral delivery of ACE2/Ang-(1-7
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $225,000
Sep 19, 2019 – Aug 31, 2020
Solicitation PA18-574 (2018) · Topic NHLBI
Development of a Novel Therapeutic for Hyperthyroidism
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $225,000
Sep 17, 2019 – Aug 31, 2020
Solicitation PA18-575 (2018) · Topic NIDDK · Research partner: UNIVERSITY OF FLORIDA
Prevention of White Matter Injury in Premature Infants
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $223,899
May 17, 2019 – Apr 30, 2020
Solicitation PA18-575 (2018) · Topic NICHD · Research partner: UNIVERSITY OF FLORIDA
Personalized dosing of dichloroacetate for the treatment of rare and common diseases
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $1,488,962
Jul 1, 2017 – Aug 31, 2019
Solicitation PA15-270 (2015) · Topic NICHD · Research partner: UNIVERSITY OF FLORIDA
Development of CaSR nutrient therapy for childhood diarrhea
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $223,899
Apr 1, 2017 – Mar 31, 2019
Solicitation PA16-303 (2016) · Topic NICHD · Research partner: UNIVERSITY OF FLORIDA
Next generation quantitative HCV drug resistance assay
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $232,433
Apr 1, 2017 – Mar 31, 2019
Solicitation PA16-303 (2016) · Topic 300
Personalized dosing of dichloroacetate for the treatment of rare and common diseases
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $224,978
Sep 14, 2016 – Jun 30, 2017
Solicitation PA15-270 (2015) · Topic NICHD
Development of Optimized AAV Serotype Vectors for Human Gene Therapy
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $294,094
Aug 9, 2016 – Jul 31, 2018
Solicitation PA14-072 (2014) · Topic NIAID
Novel therapies for inherited muscle diseases
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $224,463
Aug 1, 2016 – Jan 31, 2018
Solicitation PA14-072 (2014) · Topic NIAMS
A method for accurate and sensitive detection of HIV drug-resistant minority variants
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $253,244
Mar 15, 2016 – Feb 28, 2018
Solicitation PA15-270 (2016) · Topic NIAID
Discovery of Oligodendrocyte Stimulators
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $217,801
Sep 30, 2015 – Sep 29, 2016
Solicitation PA14-072 (2015) · Topic 101 · Research partner: UNIVERSITY OF FLORIDA
Rapid Haplotyping procedure for determining the response of patients to DCA
SBIR Phase I · Department of Health and Human Services (Food and Drug Administration) · 2015 · $122,439
Sep 15, 2015 – Mar 31, 2016
Solicitation PA14-071 (2015) · Topic FDA
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)Primary
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with MEDOSOME BIOTEC LLC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.